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TRANSFORMATION: 
The Modern Legacy of the Avery Lab 
This cover of Search shows the pneu­
monia bacteria, surrounded by a halolike 
protective capsule (magnification: 25,000). 
Beginning in 1913, Oswald Avery, a leading 
pneumonia researcher, showed that different 
protective capsules-each a polysaccharide 
with a distinct chemical identity-surround 
different strains of pneumococcus, and are 
essential for virulence. Take the capsule 
away, and the bacterium is rendered harm­
less. When, in 1928, researcher Fred Griffith 
showed that one type of bacteria (naked and 
harmless) can be transformed into another 
(encapsulated and lethal), Avery set about 
discovering the identity of this mysterious 
chemical substance which caused the trans­
formation. Sixteen years later, joined by 
Colin Macleod and Maclyn McCarty, the 
Avery team published its landmark 1944 
paper showing that DNA was the transform­
ing principle-a substance that could cause 
a heritable change of bacterial cells. 
The Avery lab's work did not just 
uncover the genetic secret behind transfor­
mation-it was a seminal "transforming" 
moment in biology. For it was this revolution­
ary finding that set the stage for Francis 
Crick and James Watson's dramatic unravel­
ing of the double-helical structure of DNA 
in 1 953 and started a modern revolution-
in genetics, molecular biology, infectious 
disease-that continues to transform our 
lives, a transformation to which this issue 
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A Message from the President
In 1994, The Rockefeller University celebrated the 50th anniversary of what the great immunologist Peter Medawar called "the most interesting and portentous biological experiment of the 20th century": the discovery that DNA carries genetic information. This revolutionary finding by Oswald Avery, Colin MacLeod and Maclyn McCarty, the fruit of fifteen years of painstaking work in Avery's pneumonia-research laboratory at The Rockefeller Hospital, was first published in The Journal of Experimental
Medicine on February 1, 1944. As, the late Lewis Thomas wrote: "This single discovery opened the way into the biological revolution which continues to transform our view of nature in the most intimate details, and continues as well to cast up, in its wake, one biotechnology after another for the comprehension and, it can be hoped, the reversal of human disease processes." In this issue of Search, we trace both the historical roots of the Avery laboratory's 1944 paper, and an array of remarkable new discoveries that have flowed from it. "The Legacy of Avery" shows how Avery's pneumonia research program led to the DNA discovery, and how our new­found ability to read and manipulate DNA is being used by Dr. Vincent Fischetti in the continu­ing fight against infectious disease microbes. "The Bugs Are Back" describes Dr. Alex Tomasz's research and public health efforts in understanding and designing new therapies against antibiot­ic-resistant bacteria, one of the major medical problems in the world today. "Following the Thread of Life" profiles the work of five leading young DNA researchers at the university-Drs. Stephen Burley, Frederick Cross, Stephen DiNardo, Jeffrey Friedman and Titia de Lange. Dr. Friedman's recent and much-heralded discovery of the first gene linked to the regulation of body weight, providing a new foundation for the study of the molecular basis of human obesity, is a shining example of how modern DNA science is changing the face of medical research. "Opening Pandora's Box" discusses some of the ethical issues arising from our newfound knowl­edge in the context of Dr. Nancy Wexler's quest for the Huntington's disease gene. Highlights from our year-long celebration of Avery, MacLeod and McCarty's revolutionary finding are pictured in a special photo essay. A particularly exciting highlight occurred on September 30, when Professor Emeritus Maclyn McCarty received the Albert Lasker Special Public Health Award-only the fifth time in the distinguished history of the Lasker Awards that this special recognition has been given. Like Avery, Mac is a famously modest man, who would readily echo a favorite saying of his mentor's: "Apply the brakes when tempted to blow your own horn." One of the great pleasures of this anniversary year has been the opportunity for the university community and scientific world to blow the trumpet for Mac, and for the late Oswald Avery and Colin MacLeod. 
Torsten Wiesel 
President 
From Inf e-ctious 
Above, Members of the Avery laboratory, about 1932. (From left to righn, 
Seated: Thomas Francis, Jr., Oswald Avery, Walther F. Goebel. Standing: 
Edward E. Terrell, Kenneth Goodner, Rene J. Dubas, Frank H. Babers. 
It was called the "crisis." 
Ten or twelve days after the first signs of sickness, 
the pneumonia patient's fever would rise precipitous­
ly; the bacterial infection of the lungs would peak; 
the patient's immune system would either launch 
a successful attack against the invading bacteria, 
or the patient would die. One-fifth of pneumonia 
victims did not survive the crisis; four-fifths recovered. 
At the turn of the 20th century, when The Rockefeller 
Institute for Medical Research was established, lobar 
pneumonia was the nation's leading cause of fatality. 
The great English physician William Osler called 
pneumonia "Captain of the Men of Death." 
Pneumonia was, Osler said, "a self-limited disease 
which can neither be aborted nor cut short 
by any means at our command." 
For Oswald T. Avery, the key to the pneumonia 
crisis was contained in small vials of sugar. Between 
1913, when he was recruited to work on pneumonia 
therapy at The Rockefeller Hospital, and the late 
1920s, Avery and several brilliant collaborators 
discovered that these complex sugars, or polysaccha­
rides, composed the protective capsules surrounding 
pneumococci bacteria, shielding them and preventing 
their engulfment by bacteria-eating immune cells 
called phagocytes. 
Different types of pneumococci were protected 
by capsules made of different polysaccharides. 
Avery's initial research at Rockefeller was aimed at 
isolating animal antibodies against the capsules of 
different pneumococcal types, which could then be 
injected into human pneumonia patients before they 
reached the crisis. Until the advent of antibiotics, this 
"serum therapy" was medicine's only weapon against 
lobar pneumonia. 
This work helped usher in the era of antibiotics, 
The Legacy of Avery: 
Disease to DNA 
and in the process established the paradigm for the 
modern study, diagnosis and treatment of all infec­
tious diseases. And it was a mysterious phenomenon 
involving this sugary capsule that also led Avery, 
Colin Macleod and Maclyn McCarty to what the 
Nobel Prize-winning immunologist Peter Medawar 
has called "the most interesting and portentous bio­
logical experiment of the 20th century" -the demon­
stration that genetic information is carried by DNA. 
Launching the Antibiotic Era 
In his account of this discovery, The 
Transforming Principle, Maclyn McCarty has 
described Avery's tenacious genius: "an uncanny abil­
ity to ask the right questions [about a scientific prob­
lem] and a dogged persistence in finding the answers." 
Rockefeller's Rene Dubos also described this talent 
in his account of his first meeting with Avery in 1927, 
when the two discovered their intersection of interests 
over lunch. Dubos told Avery how he had discovered 
enzymes secreted by soil bacteria that decompose 
cellulose, the polysaccharide that gives plants their 
stiffness. Avery immediately remarked that this plant 
polysaccharide was related in chemical structure to 
the polysaccharide composing the capsule of the most 
deadly of pneumococcal strains, called Type III. 
"As if by a casual gesture, but in fact deliberate­
ly," wrote Dubos, "Avery took from the right-hand 
drawer of his desk a little tube containing a white 
powder, labeled in his neat handwriting SSSIII, and 
shook it in front of me." Still shaking the capsule, 
Avery said to Dubos: "This is the polysaccharide of 
which the capsule is made. It is completely resistant 
to the body enzymes and to all other enzymes we have 
used . ... If only we knew of a way to decompose it 
with an agent mild enough to be used in the body-an 
by Geoffrey Montgomery 
enzyme, for example-much could be learned about 
pneumococcal infections." 
Dubos found himself fascinated by this challenge. 
A year later, in the summer of 1928, he discovered 
an enzyme made by soil bacteria in the cranberry bogs 
of New Jersey that could specifically break down the 
Type III pneumococcal capsule. The enzyme, called 
SIII, cured pneumonia in experimental mice, but it 
could not be used in humans because it had to be 
injected directly into the lungs. The discovery did, 
however, lead to the isolation of more easily adminis­
tered antibiotics, and it launched the antibiotic era. 
DNA: The Transforming Substance 
Also in 1928, the British medical scientist 
Fred Griffith discovered a mysterious transformation 
that would lead to the most spectacular of the Avery 
laboratory's achievements. Griffith injected into mice 
Type II pneumococci that had lost the ability to make 
a protective capsule; these naked bacteria were harm­
less, easily swallowed by immune cells. Griffith simul­
taneously injected killed Type III pneumonia bacteria 
into the mice-also harmless. Yet the mice died; and 
from their bodies Griffith recovered living, and vim-
Above, Transformation of pneumococci from harmless, denuded form 
(lefrj to virulent, encapsulated form (righrj studied by Avery, Macleod 
and McCarty and published in the 1944 landmark paper. 
. .... 
lent, Type III bacteria. 
The dead Type III pneumococcus had not been 
miraculously resurrected. Rather, as the Avery lab 
soon established, the dead Type III bacteria were 
transferring some unknown chemical, dubbed "the 
transforming substance," to naked Type II cells that 
allowed them to grow a protective Type III capsule. 
From a purified transforming 
extract, Avery wrote, "there sep­
arates out a fibrous substance 
which on stirring the mixture 
wraps itself about the glass rod 
like thread on a spool." 
And the transformed cells 
passed on this new property 
to their descendants. 
As Avery had earlier pur­
sued the chemical composition 
of the capsule responsible for 
pneumococcal virulence, so 
he and two young colleagues, 
Colin MacLeod and Maclyn 
McCarty, now sought between 
1934 and 1944 the chemical identity of the substance 
responsible for this transformation. 
"Some job-full of heartaches and heartbreaks," 
wrote Avery in 1943 to his brother Roy, a bacteriolo­
gist at Vanderbilt. "But at last perhaps we have it." 
From a purified transforming extract, Avery wrote, 
"there separates out a fibrous substance which on 
stirring the mixture wraps itself about the glass rod 
like thread on a spool." The threadlike transforming 
substance was deoxyribonucleic acid, or DNA-the 
thread of life. 
From DNA Back to Infectious Disease: 
The Modem Synthesis 
Avery, MacLeod and McCarty published their 
revolutionary finding in the February 1, 1944 issue 
of The Journal of Experimental Medicine. Fifty years 
later, this discovery has transformed biological 
science. Yet humankind has remained plagued by 
infectious diseases, from tuberculosis to the AIDS 
virus to a recent outbreak of deadly streptococcal 
strains. And it is only relatively recently that the two 
strands of the Avery lab's research-in infectious 
disease and DNA-are being wound together like the 
two strands of the double helix itself. 
Studies by Rockefeller scientists and others have 
made it clear that the kind of DNA-mediated transfor­
mation studied by Avery and his colleagues was no 
laboratory curiosity; it is one of several natural mech­
anisms bacteria use in their constant struggle for 
survival. As antibiotics course through the bodies 
of antibiotic-treated humans and animals, the bacteria 
living inside evolve and resist these drugs. [See page 
20 of this issue.] 
Antibiotic resistance has highlighted the need 
for vaccines against bacterial pathogens. And here 
also the work of Avery and his colleagues continues 
to serve as a guiding light. In the 1940s, Michael 
Heidelberg and MacLeod-two descendants of the 
Avery lab then at Columbia University and New 
York University, respectively-developed the first 
pneumonia vaccine. The vaccine was made up of 
polysaccharides isolated from eight types of pneumo­
cocci. Yet with the advent of antibiotics, the use of 
this pioneering vaccine was abandoned, although 
Robert Austrian of the University of Pennsylvania 
School of Medicine, who had worked with MacLeod 
at NYU, later led a heroic scientific and public health 
effort to develop an improved version. And, in the 
late 1960s, Rockefeller Professor Emil Gotschlich 
also pioneered a new type of polysaccharide vaccine­
against the bacteria that cause meningitis. 
Polysaccharide vaccines work by inducing the 
body to generate antibodies that bind to specific types 
of bacterial surfaces. Such vaccines do not evoke so­
called "cellular immunity," however, which is mediat­
ed by specialized immune cells called T lymphocytes. 
While adults can overcome bacterial infection solely 
with antibodies (produced by B cells of the immune 
system), children require a T cell response as well. 
T cells are unable to recognize a polysaccharide in 
isolation; the polysaccharide must be linked, or 
"conjugated," to a larger molecule, such as a protein. 
The first experimental conjugate vaccine, which 
chemically joined a crucial piece of pneumococcus 
polysaccharide with the albumin protein of egg white, 
was pioneered by Walther Goebel and Avery in 1931. 
Yet it was not until 1987 that the first conjugate 
vaccine, developed by John B. Robbins and his col­
leagues at the National Institutes of Health, was 
licensed for clinical use. The vaccine was targeted 
against Hemophilus influenza Type B, which infects 
1 of every 250 children in the United States, killing 
10% of those infected, and leaving another 30% with 
permanent afflictions such as blindness or deafness. 
Left, M proteins, which shield Group A strepto-
cocci from immune cells, appear as hairlike 
filaments covering the surface of bacterial cells. 
The basis of the vaccine, says Robbins, was laid 
in the paper published in 1931 in The Journal of 
Experimental Medicine by Goebel and Avery. 
No example better illustrates how the twin 
strands of the Avery lab's research in infectious disease 
and DNA have been fused in modern research than 
the work of Rockefeller Professor Vincent Fischetti 
on streptococcal vaccines. Streptococci cause not only 
strep throat, but rheumatic fever-and in rare cases 
of a toxin-producing strep bacteria infected by a 
toxin-producing virus, sudden necrosis of the body's 
tissue and even death. Following the pioneering trail 
of Avery's colleague at Rockefeller, Rebecca Lance­
field, Fischetti and his co-workers have studied how 
streptococci protect themselves from human immune 
cells through surface molecules called M proteins. M 
proteins play an analogous role to the polysaccharide 
capsule shielding pneumococci; they protect the bacte­
ria from engulfment. But the 80 known streptococcal 
strains possess 80 different types of M proteins. 
After cloning the DNA encoding the M protein, 
Fischetti and his colleagues discovered both a region 
of the M protein that was shared among the 80 differ­
ent streptococcal M proteins and a region common 
among nearly all bacteria classified as gram-positive, 
which includes the pneumococcus and the bacteria 
responsible for staphylococci infections. This latter 
conserved region serves to anchor proteins like the 
M protein on the surface of the gram-positive bacte­
ria. By genetically splicing this anchor sequence along 
with the M protein common region into a harmless 
bacteria that normally colonizes human teeth and 
gums, Fischetti and his colleagues have been able 
to design a recombinant DNA vaccine that elicits 
antibody production against the different types of 
streptococcal M protein. The vaccine, which has 
proven to be effective in animal studies, is scheduled 
to undergo clinical trials in late 1995. 
While conventional vaccines are delivered 
through the bloodstream, Fischetti's works at the 
mucosal surface-the membranous lining of the diges­
tive, respiratory and reproductive system where 90% 
of microbial infections begin. Such mucosal vaccines, 
says Fischetti, "have changed our thinking, and a lot 
of other people's thinking, about how to develop safe 
and effective vaccines. If you block the entrance of 
the pathogen at the mucosal surface, you can circum­
vent all kinds of complications that occur once the 
pathogen has entered into the body's tissues." 
The conserved M protein anchor region identified 
by Fischetti's group has also led them to identify 
another possible target for antibiotics, one that would 
be effective against all strains of strep and other gram-
positive bacteria. The attachment of M proteins to the 
bacterial cell wall requires a specific enzyme; without 
this enzyme, the bacteria cannot construct its protec­
tive M protein shield. Fischetti's lab is working to iso­
late this enzyme. A substance that would specifically 
inhibit the function of this essential bacterial enzyme 
might serve as a novel type of antibiotic. 
The conserved anchor region of the M protein 
can also be genetically fused to the DNA encoding a 
target protein used by any pathogenic microbe, from 
pneumococci to the AIDS virus. "You just cut and 
paste DNA," says Fischetti. Hybrid DNA molecules 
can then be transferred into a harmless bacteria, 
where the target protein of the pathogenic microbe 
will be anchored to this innocuous bacteria's surface. 
Once introduced into humans, the immune system 
will generate antibodies against the target protein 
displayed on the surface of the bacteria, providing 
immunity against a pathogenic microbe that has 
never been previously encountered. 
"The investigations carried out by Avery and 
his school," wrote Dubos, "have provided the 
pattern, the master plan, used by our generation for 
the immunochemical study of infectious processes." 
With today's ability to read the DNA inside an 
infectious microbe to better understand how it causes 
disease, and to rewrite DNA to design new drugs and 
vaccines, it is clear that Avery's master plan for infec­
tious disease research is a legacy that endures. � 
Above, Dr. Vincent A. 
Fischetti and his col­
leagues use recombi­
nant DNA technology 
to design vaccines 
applicable to a wide 
variety of pathogenic 
microbes. 

Fifty years ago, Rockefeller 
scientists Oswald Avery, 
Colin Macleod and Maclyn 
McCarty pubI ished the paper that
launched a biological revolution. 
Their research disclosed that DNA 
is the stuff of genes, its threadlike 
fibers endowed with the instruc­
tions for weaving the intricate 
tapestry of life. 
Researchers around the world 
have been pursuing the thread of 
life ever since. In the 1950s, DNA's 
double-helical structure was 
unveiled. In the '60s, the 
genetic code was deciphered 
and its mode of translation 
into proteins revealed. In the 
'70s, the complex nature of 
genes in higher organisms 
was discovered. In the '80s, the 
techniques of genetic engineering 
were refined. In the '90s, the effort 
to map humanity's entire genetic 
endowment began, and the first 
experiments in gene therapy 
by Susan Blum 
got under way. 
But despite these exciting 
advances, countless questions 
remain. How is DNA conserved 
and protected within the nucleus? 
What controls its cycles 
� of replication and distrib­
ution? How is the read­
out of genetic informa­
tion regulated? How do 
the genes control life's 
processes, including the develop­
ment of new life itself? What con­
tributions do genes make to dis­
ease, and how can those culprit 
genes be found? 
The answers to these ques­
tions - and many more - are 
being sought by a new generation 
of researchers at Rockefeller, who 
continue the legacy of DNA 
research begun half a century ago. 








After Aveiy and his colleagues dis­
covered that DNA carries genetic 
information in bacteria, scientists 
came to realize that DNA is the 
stuff of genes in all creatures, 
including humans. In each living 
cell, the genes are aligned next 
to one another on chromosomes. 
Bacterial cells, which have no 
nucleus, carry their entire genetic 
endowment in one circular chro­
mosome. But the genes in the 
nucleated cells of higher organisms 
are distributed along multiple lin­
ear chromosomes-and therein 
lie potential problems. 
For one thing, the cellular 
machinery that duplicates linear 
chromosomes in each cycle of cell 
division cannot copy their very 
ends, thus posing the risk that 
the chromosomes will eventually 
be whittled right out of existence. 
For another, if left unprotected, 
the ends of linear chromosomes 
are subject to loss through fusion 
with one another or degradation 
by cellular enzymes that patrol for 
dangerous breaks in DNA. 
Telomeres-the subject of 
study in T itia de Lange's lab­
apparently solve both these prob­
lems. Telomeres are complexes of 
specialized proteins and repetitive 
DNA sequences that cap the ends 
of linear chromosomes. T hey solve 
the "end-replication problem" by 
interacting with an enzyme called 
telomerase, which adds back the 
DNA that would otherwise be lost 
when the chromosome is duplicat­
ed. And they solve the problem of 
potential fusion and degradation by 
disguising chromosome ends from 
the cell's enzymatic surveillance 
mechanisms. 
Ironically, the two functions 
of the telomeric complex are inher­
ently self-contradictory, hiding the 
DNA from the patrol enzymes 
while handing it over to the telom­
erase. Says de Lange, "It's obvious 
to most people that the resolution 
of this contradiction is going to lie 
in the interactions between telomer­
ic proteins and DNA." But though 
the DNA of telomeres has been 
under study for more than fifteen 
years, very little is yet known about 
the proteins associated with it. 
de Lange and her colleagues 
are hunting for telomeric proteins 
in vertebrates, and so far they have 
found two candidates. One might 
coat the entire length of the telo­
mere; the other recognizes the 
repetitive telomeric DNA only at 
the telomere's very end. 
de Lange is investigating 
whether these proteins play a role 
in interacting with or regulating 
telomerase, an enzyme of intense 
interest to cell biologists. Telo­
merase is thought to be active in 
germ-line cells, the progenitors of 
the sperm and egg cells that trans­
mit genes to the next generation. 
There, the enzyme ensures that 
the myriad rounds of replication 
involved in producing the cells 
do not shave down their precious 
genetic inheritance. In most cells 
of the body, though, telomerase is 
normally inactive, and the chromo­
somes are progressively whittled 
down. 
Some scientists believe this 
shortening may trigger the work­
ings of a cellular clock that ticks 
off the number of cell divisions and 
eventually tolls the cell's senescence 
and death. 
But some cells never die. 
These are the cancer cells that 
evade mortality and divide prodi­
giously, perpetuating their deadly 
genetic mutations. At first (as de 
Lange discovered while still a post­
doc) the chromosomes in cancer 
cells shorten with each replication 
cycle, just as in normal cells. But 
recent studies have shown that at 
some point cancer cells turn telom­
erase back on, thus stabilizing the 
cancer cell's chromosomes and per­
haps overriding cellular controls 
triggered by ever-shortening 
telomeres. 
Researchers are hopeful 
that drugs against telomerase 
might be a new weapon in the war 
against cancer-one that targets 
cancer cells while leaving healthy 
cells alone. 
But de Lange points out, 
"We need to get down to basics 
first. We must understand in detail 
what telomeres are to a cell and 
what happens to a cell when it loses 
them. As long as we don't under­
stand that, it's hard to draw any 
conclusions about tumor forma­
tion, or even about normal aging." 
Given the many novel discoveries 
that have emerged from telomere 
research so far, there may well turn 
out to be additional surprises found 
lying at what de Lange calls "the 
far side of the genome." [!] 
Left, Telomeres are complexes of specialized 
proteins and repetitive DNA sequences that cap 
chromosome ends. In human cells, the character­
istic DNA repeat consists of six bases: TTAGGG, 
or thymine-thymine-adenine-guanine-guanine­
guanine. (The second strand of the DNA double 
helix is of course composed of the complemen­
tary base partners.) Telomeres are very long; 
in humans, they extend for thousands of 
base pairs. 
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Perhaps as good a definition of life 
as any is that life is order. To per­
petuate that order, the information 
carried in DNA must be faithfully 
transmitted to each new generation 
of cells-be they the somatic cells 
that make up most of the body, or 
the specialized sperm and egg cells 
that pass chromosomes on to the 
next generation. 
The process by which this 
order is maintained is the cell cycle 
-the tightly regulated sequence
of events in which a cell grows,
duplicates its chromosomes, and
bequeaths them to the "daughter"
cells into which it divides. In the
past decade, research in a wide
range of cells-from those of yeast
to those of vertebrates-has been
converging into a single, highly
unified picture of how the cell
cycle works in eucaryotic cells,
or cells with a nucleus.
Remarkably enough, much of 
this progress has occurred through 
what Fred Cross calls "a crazy 
update" of the experiments con­
ducted by Avery and his colleagues 
half a century ago. In this modern 
version, genes are not transferred 
between different strains of the 
same species (as Avery did with 
pneumococci, for instance) to elicit 
new traits in the recipient cells. 
Rather, genes are transferred 
between cells of species as different 
as yeast and humans, where they 
are found to perform exactly the 
same functions in each. The 
reason: The genes are so essential 
to the workings of eucaryotes that 
they have been conserved virtually 
unchanged across billions of years 
of evolution. 
The genes thus identified code 
for proteins that play vital roles 
in cell cycle control. Many events 
occur in this cycle, which is gener­
ally divided into four phases. In the 
first phase, G 1 (for "gap l "), the 
cell grows and, at a critical point, 
commits to reproducing its DNA. 
Associate Professor, The Rockefeller University 
Once this starting line is crossed, 
a slew of events occurs in the next 
phase, called S (for "synthesis")­
including the replication of chro­
mosomes. The second gap phase 
(G2) follows, during which the cell 
makes another commitment-
this time, to divide in two. After 
this critical point, the cell enters 
the M phase, named for mitosis­
the division of the cell's nucleus 
that is one of the last steps leading 
up to cell division. 
The first insights into control 
of the yeast and vertebrate cell 
cycle came from studies of the 
transition from the G2 to M 
phase. Experiments disclosed 
how a particular enzyme, a type 
known as a kinase, serves as the 
master regulator that triggers 
mitosis. This molecule is actually 
composed of two subunits. The 
catalytic part, called a cdk, is pre­
sent in constant amounts through­
out the cell cycle. But the kinase 
can act only when teamed up with 
another subunit, called a cyclin, 
whose abundance varies at 
different times in the cycle. 
Later experiments showed 
that the same basic scenario works 
to regulate events in the transition 
between the GI to S phase, when 
cdk molecules team up with cyclins 
( different from those involved in 
the M phase) to orchestrate the 
events culminating in chromosome 
replication. This cell cycle stage 
is the focus of work in Cross' lab, 
where he and his colleagues are 
studying the function and regula­
tion of genes coding for a family 
of yeast G 1 cyclins called CLN s. 
The cell cycle story has taken 
on even greater complexity with 
the discovery of proteins in both 
yeast and humans that inhibit the 
activity of cdk/ cyclin complexes. 
The first protein ever to be identi­
fied as an inhibitor�called FAR 1 
-is a yeast protein also under
study in the Cross lab. The
1ne Cell Cf (le 
Mitotic kinase triggers 
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G1 cyclin breaks 
down 
Rockefeller researchers' recent dis­
covery that levels of FAR 1 rise and 
fall cyclically will help further re­
fine current models of the intricate 
networks controlling the cell cycle. 
Today's cell cycle studies may 
one day lead to advances in under­
standing and treating cancer, a 
disease of unrestrained cell growth 
and division. Says Cross, "It always 
made sense that links would exist 
between cell cycle control and 
cancer, but only in the past year 
or so have those links become real, 
rather than speculative." For 
instance, one inhibitory protein has 
been tied to cellular pathways regu­
lated by a tumor-suppressor gene 
called p5 3. Researchers have also 
learned that the deregulation of 





Start kinase triggers 
DNA synthesis 
Above, The cell cycle has four phases: GI 
(for "gap I"); S (for "synthesis" of DNA); G2 (for 
"gap 2"). and M (for "mitosis," or cell division). 
Master molecules called kinases trigger the two 
main events of the cell cycle-the duplication 
of DNA and the division of the cell into two prog­
eny. The kinases are composed of two subunits. 
The catalytic parts, called cdks, are present in 
constant amounts throughout the cycle. But the 
kinases can act only when teamed up with other 
subunits, called cyclins, whose abundance varies 
at different times in the cycle. 
Illustration by Terese Winslow 
help transform a normal cell into 
a cancerous one. With an ever­
increasing understanding of the 
intricately choreographed steps 
regulating the cell cycle, it may 
someday be possible to stop the 
music when the molecular dancers 
start spinning wildly out of control. C!J 
...... 
�e�uireO �eaOin�: 
Mo ecu ar 
Macnine� 
Control Cellj' DNA 
�eaOout 
In the lab of Stephen Burley, 
When the seminal paper by Avery 
et al. was published, DNA-with 
its mere four chemical subunits­
was widely believed too "stupid" 
a molecule to carry all the informa­
tion required to construct and 
maintain even the simplest life 
forms. But in the two decades 
that followed, the wisdom of DNA 
was revealed, as researchers deci­
phered its code and showed how 
genes serve as the blueprints for all 
the proteins an organism requires. 
In complex multicellular 
organisms, every cell possesses a 
full complement of genes, but turns 
only some of them on. Each differ­
ent cell type thus produces a dif­
ferent array of proteins. And, as 
Stephen Burley explains, it is these 
differences in protein content that 
make "a liver cell resolutely a liver 
cell, a skin cell resolutely a skin cell." 
Genes are turned on in tran­
scription, the process by which 
DNA is read out into a closely 
related molecular intermediate 
called messenger RNA. (In a later 
step, the instructions in messenger 
RNA are then translated into 
protein.) Transcription is accom-
plished by complex molecular 
machines that forge intricate rela­
tionships between DNA, a copying 
enzyme called polymerase, and 
transcription factors that interact 
with the DNA, the polymerase, 
or both. Some transcription factors 
serve as molecular bookends, posi­
tioning the copying enzyme at the 
proper place to start a gene's read­
out. Other factors act as accelera­
tors or brakes, controlling the speed 
of transcription and ensuring that 
only certain genes are read out in 
certain cells. 
Burley and his colleagues 
explore the workings of these mole­
cular machines on an atom-by-atom 
basis, using the technique called 
x-ray crystallography. T heir studies
of DNA/protein interactions have
disclosed a submolecular world of
astonishing beauty and variety. For
instance, they have shown that TBP,
a positioning factor, sits astride
DNA like a saddle, while HNF-3,
an activating factor, envelopes DNA
with gossamer butterfly wings.
Just as the work of Avery and 
his colleagues revealed that DNA 
was not as stupid as once believed, 
so current explorations disclose that 
DNA is not as static as the famous 
double-helical structure used to 
imply. In fact, crystallographic stud­
ies show that DNA may undergo 
dramatic conformational changes 
when in the grip of the transcrip­
tional machinery. For example, 
Burley and his colleagues found 
that when the TBP saddle drops 
over DNA, the DNA twists more 
than 100 degrees from its normal 
orientation. Likewise, they showed 
that some activating and repressing 
factors cause DNA to bend and 
loop, bringing hitherto-distant 
gene regions into close proximity. 
Transcription factors can also 
� t e � Pro�ot�efeller u��i� r I e �Investigator, the Howard Hughes �edical lnstJrute 
affect DNA's higher organization. 
Normally, DNA is spooled around 
proteins called histones. Such 
packaging corrals the mind-bog­
gling six feet of DNA found in each 
cell, but it also hinders transcription 
by hiding essential gene-control 
regions. (Indeed, many scientists 
believe that such hindrance by his­
tones is a vital component of tran­
scriptional control, not merely a 
troublesome by-product of a cell's 
DNA packaging needs.) Now, 
recent studies by Burley and others 
are showing that transcription fac­
tors can affect DNA/histone inter­
actions in ways that alter DNA's 
usual patterns of nesting within 
the nucleus. 
Says Burley, "It is becoming 
clear that to know how the right 
gene gets transcribed at the right 
time, we will have to understand 
not only protein/protein and pro­
tein/DNA interactions, but the 
much larger questions of DNA 
structure and organization, as well." 
The more scientists learn about 
the machinery that controls gene 
activity, the better their chances 
of eventually tinkering with those 
machines for their own therapeutic 
purposes. 
For instance, part of the 
process that turns a cell cancerous 
involves the deregulation of tran­
scriptional controls. By throwing 
molecular monkey wrenches into 
transcriptional machines gone 
amok, scientists may someday be 
able to slow or even halt the pro­
gression of cancer. They may also 
be able to construct their own 
transcription machines from 
scratch, to safely and accurately 
regulate foreign genes delivered 
in gene therapy for a wide range 
of diseases. The ultimate goal, 
says Burley, is to enlist knowledge 
gained from crystallographic studies 
"not only to understand transcrip­
tion, but actually to control it in 





How DNA Weaves 
the Fabric of Life 
Cells Cells contain many structures and perform 
many functions crucial for life. Their workhorses are 
proteins, the molecules that shore up a cell's structure, 
control its chemical reactions, and determine which 
substances enter and leave. 
Chromosomes Chromosomes are the struc­
tures that package DNA, the substance encoding the 
instructions for proteins. Some organisms sequester 
their chromosomes within a cell nucleus; others do not. 
DNA DNA is a double-stranded helical molecule 
composed of four different subunits, or bases -
Adenine (A), Thymine (T), Guanine (G) and Cytosine (C). 
Within the helix, the bases always link up with a partic­
ular partner: A pairs only with T, G only with C. 
Genes A gene is an information-carrying segment 
of DNA. Genes can be thousands or even hundreds of 
thousands of base pairs long. The information in each 
gene is different, depending on the order in which the 
bases are arrayed in the gene. Most genes contain the 
information for constructing proteins. 
Proteins Proteins are long chains of amino acids 
linked one to another. Different sequences of DNA 
bases code for different amino acids. The cell reads out 
this code in a series of intricate steps. First, one strand 
of DNA is transcribed into a closely related molecular 
intermediate called RNA. Then the cellular machinery 
translates RNA into proteins. The unique order of bases 
characteristic of each individual gene gives each protein 
its unique identity. Proteins serve many different func­
tions and give cells their essential characteristics. 
Illustration by Terese Winslow 
Associate Professor, The Rockefeller University 
Stephen OiNardo and 
co-workers are pursuing 
the principles that control 
how embryos t 
The genes that get read out into 
proteins do more than maintain an 
organism's everyday life. They also 
control the emergence of new life 
itself, in what Stephen DiNardo 
calls "the mystique and the magic" 
of embryologic development. 
Development consists of a 
series of choices. The original 
fertilized egg has the potential 
to become every type of cell the 
mature organism will require. 
But with each round of successive 
cell division, the options for each 
daughter cell grow progressively 
limited, as the cells make choices 
that nudge them closer to their 
final identity. These choices are 
made manifest in the emergence 
of cellular patterns of ever-increas­
ing complexity within the embryo. 
At each step, the decisions are 
dictated by positional information 
that tells a cell where it is in rela­
tion to other cells in the emerging 
cellular pattern. 
Researchers in the DiN ardo 
lab are investigating how positional 
information specifies the ten or 
so different epidermal cell types in 
the fruit fly embryo. Each differen­
tiated cell type has a different shape 
and boasts a particular surface 
appearance. Some cells are smooth, 
while others sport a little hair, or 
denticle, of a characteristic length, 
thickness and orientation. 
While a fly's prickly surface 
might not seem very aesthetic, 
it is yielding elegant information 
about embryonic choices-includ­
ing some made in the earliest stages 
of development. 
During that early period, 
positional information is conveyed 
to a cell from "organizing centers," 
areas that serve as sources of signals 
directing the differentiation of 
large numbers of cells into many 
different cell types. 
Scientists have known about 
organizing centers since the 1930s, 
but the search for the signals they 
send has long been fruitless. 
Recently, however, researchers 
from a number of labs identified 
the first such signaling molecules in 
vertebrates, and found that they all 
belonged to the quirkily named 
"hedgehog" family of proteins. 
Though these discoveries were 
loudly trumpeted in the press, the 
initial identification of the hedge­
hog gene, and of the crucial role it 
plays in development, was actually 
accomplished in the mid-1980s 
in work done in the fruit fly. 
That hedgehog genes are proving 
important in so many different 
species comes as no surprise to 
biologists, who keep finding that 
the fundamental principles-and 
molecules-controlling develop­
ment are the same in all animals. 
Many significant findings 
about hedgehog proteins in fruit 
flies are being made in DiNardo's 
lab, where he and his colleagues are 
studying the role of hedgehog and 
another protein called wingless. 
Their research has disclosed a 
two-phase process of interactions 
between cells that express either 
hedgehog or wingless. In the first 
phase, these cells signal each other 
over short distances to stabilize 
hedgehog and wingless production. 
This stabilization creates two 
organizing centers that serve as 
continuous sources of hedgehog 
and wingless proteins, which then 
act over a distance to specify the 
fate of several different epidermal 
cell types. 
DiN ardo believes that this 
two-phase model will prove to be, 
a general one, not only in flies but 
in vertebrates, too. But while the 
overall plot line may stay the same, 
the players will vary. In both flies 
and vertebrates, although a limited 
number of conserved families of 
signaling molecules keeps turning 
up (including hedgehog-type mole­
cules and wingless-type molecules) 
they interact with each other in 
various combinations. 
DiN ardo is not disconcerted 
by these variations. "There will 
be perhaps three or four different 
ways in which molecules like 
hedgehog can act, and nature will 
use them at different times and in 
different places in the development 
of different organisms," he says. 
Insights like these would not 
have been possible without the 
revolution begun by Avery and his 
colleagues. Before then, develop­
mental biologists were limited to 
observing the effects of positional 
information by moving various 
parts of tissue around in the 
embryos of animals such as chicks 
and frogs. Today, researchers can 
also use the powerful tools of 
genetics in invertebrates such as 
flies and worms, and then analyze 
the function of those genes directly 
Above, Each different cell type in a fruit fly's 
epidermis has a different shape and appearance. 
Some are smooth, while others sport little hairs 
of various lengths, thicknesses and orientations. 
in virtually any species, using the 
techniques of molecular biology. 
As their studies continue to disclose 
the essential mysteries of develop­
ment, and the fundamental similar­
ities of this process in all organ­
isms, it is clear why DiNardo 
says, "This is really a very 
exciting time." � 
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Gene Huntin�: 
1ne �earcn for tne 
Genetic �oot� 
of Di�ea�e 
Jeffrey Friedman and 
Half a century has passed since Avery 
and his colleagues showed that the 
secret oflife lies in DNA. But until 
very recently, most of those secrets 
lay tantalizingly out of reach, due to 
a lack of lures and hooks with which 
to fish out individual genes from the 
ocean of DNA possessed by each 
organism. 
Within the past decade, howev­
er, molecular biology has provided 
the tools that let scientists identify� 
and analyze individual genes of inter­
est. As the newspaper headlines 
attest, some of the genes of greatest 
interest are those that, singly or in 
combination, cause or contribute 
to the many diseases that plague 
mankind. Among those diseases is 
obesity, a condition associated with 
such potentially life-threatening 
health problems as diabetes and high 
blood pressure. Recently, Jeffrey 
Friedman and his colleagues took 
a major step toward identifying one 
of the genetic contributors to obesity 
by cloning-or pulling out from the 
chromosomes-a gene, called ob, 
that may play a central role in weight 
control. 
Studies have shown that from 
60 to 90 percent of the differences 
in people's weights is due to their 
genes. For many years, researchers 
had hypothesized that these genes 
play roles in a complex feedback 
system that maintains body weight at 
a particular set point. Such a system 
would involve signals from points 
in the body's periphery ( the fat cells, 
for instance) that reach receptors in 
a brain region called the hypothala­
mus (and perhaps elsewhere, too) 
to report on how much the body 
currently weighs and how well it 
has recently been nourished. T he 
brain in turn would regulate various 
responses-such as energy expendi­
ture and food intake-to keep body 
weight steady. In such a complex 
system, problems anywhere along 
the pathway-a faulty signal, for 
instance, or a defective receptor-. 
could lead to obesity. 
To clone the genes involved 
in this system, researchers turned to 
the laboratory mouse, a genetically 
well-understood creature in whom at 
least five different genes are known 
to cause obesity in various strains. 
Friedman and his colleagues set their 
sites on finding two of these genes: 
ob ( or obesity), which previous stud­
ies had indicated might code for the 
signaling molecule, and db ( or dia­
betes), which appeared to code for 
its receptor. 
By employing a method called 
"positional cloning," Friedman and 
his colleagues recently cloned the 
mouse ob gene. (See "How to Find 
a Disease-causing Gene," right). 
Subsequent analysis of the gene has 
�riedman 
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provided much evidence suggesting 
that ob may indeed code for a signal­
ing molecule, produced by fat cells, 
that sends a message to the hypothal­
amus to reduce food intake and/ or 
boost energy expenditure once the 
fat cells have reached a certain mass. 
Experiments to confirm ob's signal­
ing role are now under way in 
Friedman's lab, as are studies to 
positionally clone the db gene. 
Friedman and his colleagues 
have found that the ob gene is 
conserved, or similar, in many verte­
brates from eels to humans, whose 
ob gene shares an 84 percent similar­
ity to that of the mouse. Such con­
servation suggests that a feedback 
system for weight maintenance has 
been in place for eons, and that the 
genes controlling this system have 
been subjected to intense selective 
pressure. 
"Humans evolved in an environ­
ment where getting enough calories 
was difficult, so selection might have 
favored versions of the genes that 
allow us to deposit food efficiently 
as fat," Friedman says. Once highly 
adaptive, these versions of the genes 
would now be maladaptive in envi­
ronments such as the United States, 
where sufficient calories are avail­
able to many-and where the rate of 
obesity has soared to 30 percent. 
Some of the strongest evidence 
in support of evolutionary pressure 
on weight maintenance genes comes 
from studies of aboriginal popula­
tions such as the Pacific Islanders of 
Micronesia, who now have extremely 
high rates of obesity and diabetes. 
"In general, the more severe the 
environmental conditions in past 
history, the more profound the obe­
sity in modem times," Friedman 
says. Studies of such populations 
offer extraordinary opportunities to 
answer the fundamental question 
about genes like ob, to wit: Is their 
role in human obesity as clear as 
their role in the rodent form of the 
disease? Friedman and his colleagues 
are now collaborating with residents 
of the Micronesian island of Kosrae 
to answer this question. 
The confirmation of ob's role in 
human weight maintenance would 
open up many exciting possibilities 
for a "more rational approach for 
devising novel therapies for weight 
disorders, " Friedman says. Such 
therapies could be used not just to 
lower weight in the obese, but also to 
boost it in those who are profoundly 
underweight due to conditions such 
as cancer and AIDS. � 
How to Find a Disease-causing Gene 
1 . Find DNA Markers Markers are DNA sequences Marker A: Inherited with Marker B: Inherited with 
that lie close to a particular gene and are inherited with it. 
By analyzing how various DNA markers are inherited 
among members of a family in which the disease some­
times occurs, scientists can identify markers flanking the 
disease-causing version of the gene. This pinpoints the 
DNA region in Which to look for the gene itself. 
2. Assemble a Physical Map A physical map 
tells scientists how much DNA lies in the region between 
the markers, and makes further molecular analysis of the 
DNA possible. To create the map, 
DNA in different parts of the region is cloned, or 
reproduced, in vectors such as bacteria or yeast. 
These cloned DNA segments can then be aligned 
by identifying regions of overlap. 
3. ldenti& All the Genes More than one gene
may lie in the region, and scientists must identify all 
of them before homing in on the one causing disease. Only 
some of the DNA in the region makes up genes;
the rest is DNA with no known function. The genes are 
identified using various biochemical tricks to separate the 
genes from the rest of the DNA.
4. Sequence and Compare Genes A11 DNA 
is made up of just four bases, or subunits. Each gene
differs from all others in the particular sequence in which 
those bases appear. The base sequence for each gene in 
the region can be determined, and then compared with 
the sequence of the same gene as it exists in people with­
out the disease. Mutations in a gene from a person with 
the disease identify tbat gene as the culprit. 
the disease-causing gene 
in the family under study 
� 
Disease-causing gene lies somewhere 
in this region of DNA 
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SClfNCf AND PUBllC HfAlTH 
by Doron Weber 
During the past four to five years, resistance in the United 
medical practitioners, microbiolo­
gists and public health profession­
als all over the world have begun 
to voice concern over the alarming 
increase in the number of disease­
ca using micro bes that have 
Sounding the 
States range as high as $30 
billion. Tomasz believes it is 
imperative for basic 
researchers and public policy 
makers to join ranks now, 
Alarm on Antibiotic-
resistant Bacteria 
become resistant to drugs that once checked them. 
"Antibiotic-resistant bacteria are already involved 
in the spread of hospital-acquired diseases such as 
pneumonia, bloodstream and wound infections, and 
in community-acquired diseases such as tuberculosis, 
meningitis, lung and middle-ear infections across 
America," says Professor Alexander Tomasz, head of 
Rockefeller University's laboratory of microbiology 
and a world-known authority on bacterial antibiotic 
resistance. 
"As more and more common bacteria acquire 
resistance genes, many of the diseases we thought we 
had under control are coming back. We are looking at 
a problem with the potential for causing a public 
health crisis." 
Already, estimates of the annual cost of antibiotic 
?O 
before the cost in dollars is 
dwarfed by the rising toll in human lives. 
Spreading Multiresistance 
Tuberculosis, once thought to be a plague of the 
past, returned during the 1980s armed with resistance 
to several previously effective antibiotics. By 1992, 
strains of tuberculosis appeared that were resistant to 
most of the 12 potentially usable drugs in existence to 
treat it. 
Tuberculosis is only the most well publicized of 
the returning, newly resistant plagues. In 1992, over 
19,000 patients died in the U.S. of various bacterial 
infections acquired while in the hospital; and a large 
proportion of the microbes that most frequently cause 
these infections have become resistant to antibiotics, 
according to the Centers for Disease Control. The 
Above, Strand of DNA entering a pneumococcal cell. Inset, Rockefeller 
Professor Alexander Tomasz points out the dangers of antibiotic-resistant 
bacteria at a lecture organized by the Public Health Research Institute and 
sponsored by Lederle Laboratories. 
available data indicate that this problem will only get 
worse. 
For example, almost half of all the hospital iso­
lates of the bacterium Staphylococcus aureus have 
become resistant to the most useful penicillin-type 
antibiotics. This bacterium is the most frequent cause 
of wound, lung and bloodstream infections acquired 
in the hospital; and there are many strains of staph 
against which there now remains only a single effec­
tive antibiotic, called vancomycin. Moreover, the 
genes for resistance, which reside in bacterial struc­
tures or loops of DNA called plasmids, can be passed 
on not just to their progeny but also to bacteria of dif­
ferent species. 
A similar scenario is emerging among pneumo­
cocci, one of the most frequent causes of community­
acquired diseases, particularly in small children. 
Pneumococcus is currently responsible 
dish exuded a substance, called penicillin, that killed 
bacteria, penicillin and its descendants became miracle 
drugs. But man's victory over microbes proved short­
lived. While most bacteria will succumb to a powerful 
new antibiotic, a few have genes, or genetic muta­
tions, that enable them to resist the antibiotic attack, 
and these produce resistant descendants. So only the 
fittest-that is, the most resistant-bugs survive. Each 
surviving bacterium can leave over 16 million off­
spring within 24 hours. 
"On an evolutionary scale, bacteria and host have 
been facing each other and eoexisting for billions of 
years" explains Tomasz. "The discovery of antibiotics 
introduced a radically new element into this face-off. 
The devastating effectiveness of penicillins and other 
drugs introduced during the 1940s forced the micro­
bial world to mobilize its genetic resources. Today, 
after only 50 years-an incredibly 
for tens of thousands of bloodstream 
infections, 500,000 new cases of pneu­
monia and 6 million new cases of mid­
dle-ear infections each year in the United 
States. 
11 Today, after only 
short span on the evolutionary time 
scale-bacteria have developed a 
remarkable variety of mechanisms to 
resist every known usable antibiotic." 
50 years-an 
incredibly short span 
on the evolutionary 
time scale-bacteria "We now have several case descrip­
tions from the U.S. of infants with have developed a 
T he most dangerous are bacteria 
that seem to be able to collect many 
mechanisms of resistance and can thus 
gradually become resistant to all 
antibacterial agents. And these resis­
tant genes can be spread, transferred 
from one species to another, and then 
jet from one part of the world to 
meningitis caused by resistant pneumo­
cocci who are no longer responding to 
therapy by penicillins and cephalo­
sporins," says Tomasz. As a result, doc­
tors have had to use vancomycin, the 
same drug that has become a "last 
remarkable variety of 
mechanisms to 
resist every known 
usable antibiotic." 
resort" antibiotic against staphylococci as well. In at 
least one of these cases, the meningeal disease left the 
infant neurologically devastated. 
To make matters even worse, the genes providing 
bacteria with resistance to vancomycin are already 
present in yet another hospital-borne pathogen called 
Enterococcus faecium. Dr. Sandra Handwerger, clini­
cal scholar and assistant professor in the Tomasz 
lab-and one of the first to identify the biochemical 
basis of vancomycin resistance-shares the worry of 
most biochemists that these resistance genes will find 
their way into the already multiresistant and highly 
virulent strains of staphylococci and pneumococci, 
posing a potentially alarming scenario for hospital 
patients. If vancomycin fails, there is no drug current­
ly available to stop these bacteria. "Many people," 
Tomasz argues, "feel that such an event will bring us 
close to a post-antibiotic era." 
Post-Antibiotic Era 
For a brief, heady period after Alexander Fleming 
first found in 1928 that a colony of mold in his lab 
another. 
"Drug-resistant bacteria can spread geographical­
ly," says Tomasz. "The rule seems to be that wherever 
a resistant strain is reported in one part of the world, 
as time goes by it will find its way to other parts of 
the world." For example, Tomasz's lab, a world 
leader in molecular epidemiology (a method that can 
identify the offspring of resistant bacteria through 
DNA-level fingerprints), helped track the movement 
of multiply resistant clones of pneumococci: One was 
tracked between Iceland and Spain where vacationing 
Icelanders may have unknowingly picked it up. 
Another clone, most likely originating in Spain, was 
tracked literally all around the globe-to Portugal, 
France, Croatia, South Korea-and this pneumococcal 
clone has now spread widely across hospitals and day­
care centers in the U.S.; the carriers may have been 
unsuspecting travelers. 
Travel, tourism and migration have made antibi­
otic resistance a potential worldwide threat to public 
health. Tomasz argues that we have to "rethink and 
renegotiate" our whole relationship to the procaryotic 
world. 
Alex Tomasz1 A lifelong 
Scientific Commitment 
Born in Hungary, Tomasz was studying biology 
and chemistry at the University of Budapest when he 
was forced to flee the country after the Soviets 
cracked down on the Hungarian uprising in 1956. He 
arrived in New York penniless, and took a job as a 
technician at Sloan-Kettering Institute before earning 
a Ph.D. in biochemistry at Columbia University. Upon 
graduation, Tomasz, who was interested in molecular 
genetics and the surface of bacterial cells, decided to 
focus on how pneumococci manage to capture and 
internalize DNA molecules during the process known 
Above, Tomasz ponders a puzzling epidemiological triangle-a high degree of 
antibiotic resistance goes with a low degree of genetic diversity among the 
bacterial isolates-as he stands before a blackboard in his laboratory. 
as genetic transformation. 
Pneumococcus has the capacity, rare among bac­
teria, to take up free-floating strands of DNA from its 
environment. It was this capacity, dubbed "compe­
tence," that enabled the Avery lab to identify DNA as 
the carrier of genetic information in its landmark 
1944 paper. Well over a decade later, Tomasz knew 
there was still only one place to study this phenome­
non: The Rockefeller University laboratory of Rollin 
Hotchkiss, whose group had made enormous 
advances in elaborating on the discovery of Avery, 
MacLeod and McCarty. 
After joining the Hotchkiss lab, Tomasz began to 
study how the pneumococcus bacterium can recognize 
a DNA molecule in its vicinity. Through what signals 
does this recognition take place? Among his major 
findings, Tomasz discovered that competent cells of 
the pneumococcus release a protein he called "activa­
tor" that could induce the uptake of DNA in cells 
that were not yet competent. The discovery of the 
activator, the first bacterial hormc;me, and the subse­
quent studies on the DNA-bindirig transport system 
were, in a sense, a completion of Dr. Avery's discovery 
of transformation. Over the fol-' 
dations, the report called for greater awareness of the 
problem among clinical microbiologists, government 
health authorities and physicians; increased funding 
for basic research into the mechanisms of resistance; 
more adequate surveillance systems for tracking the 
spread of resistance; and a fast track for new antibac­
terial agents so that they become available for com­
passionate use in emergency situations. 
In December of 1993, Tomasz moderated a New 
York Academy of Medicine conference addressing 
antibiotic resistance in New York City clinics and hos­
pitals. The leading participants-who included Dr. 
Richard Roberts of New York 
lowing years, studies in the Tomasz 
lab have contributed richly to �1 
wide range of topics in microbiolo­
gy, such as the chemistry and bio­
logical activities of bacterial cell 
walls and the mode of action of 
penicillin; they have identified the 
molecular basis of beta lactam 
resistance in pneumococci and 
staphy lococci; and discovered 
antibiotic tolerance or the ability 
of bacteria to survive antibiotic 
treatment despite being neutral­
ized. Most recently, the lab's 
In July 1993, Tomasz Hospital and Dr. Barry Kreisworth 
of the Public Health Research 
organized a one-day 
Institute, as well as officials from 
the New York City Department of 
Health-felt such a sense of 
workshop at Rockefeller 
that brought together some 
of the nation's leading urgency that, one month later, in 
January, they formed the Bacterial 
Antibiotic Resistance Group 
(BARG). T he aim of BARG, a 
grass-roots collaboration of the 
public and private sectors, is to 
accurately tally antibiotic-resistant 
bacteria in New York City ; to 
infectious disease experts 
including those from the 
CDC, the FDA and the NIH, 
as well as the presidents of 
several scientific and 
medical organizations. 
efforts have led to the elucidation of a large number of 
auxiliary genes needed for antibiotic resistance, genes 
that may be new targets for pharmaceutical drugs. 
The Tomasz lab also pioneered in the use of molecular 
"fingerprints" for tracking the movement of drug­
resistant bacteria in hospitals in the U.S. and Europe. 
Getting the Message Out: A Busy Year 
While his lab continues to study basic problems in 
microbiology, Tomasz has begun to organize a public 
response to the emergence of disease-causing bacteria. 
In July 1993, Tomasz organized a one-day work­
shop at Rockefeller that brought together some of the 
nation's leading infectious disease experts including 
those from the CDC, the FDA and the NIH, as well as 
the presidents of several scientific and medical organi­
zations. They focused on the accelerating spread of 
pathogenic bacteria resistant to antibiotics and asked 
whether multiresistant bacteria posed a threat to pub­
lic health in the United States. T he resounding 
answer, they all agreed, was "yes." 
Nine months later, the April 1994 issue of the 
New England Journal of Medicine published the pro­
ceedings of the workshop in a special report entitled 
"Multiple-Antibiotic-Resistant Pathogenic Bacteria" 
that was authored by Toma_sz. Among its recommen-
improve infection control; to enlist 
the pharmaceutical industry and the Environmental 
Protection Agency; and to disseminate the techniques 
of molecular epidemiology to New York City 
hospitals. 
In February, Tomasz flew to San Francisco where 
his presentation on "Disease-ca using Bacteria 
Resistant to Antibiotics" was the most talked-about 
lecture at the annual meeting of the American 
Association for the Advancement of Science. 
Tomasz's warning about resistance became the num­
ber one story to emerge from the conference, reaching 
an estimated audience of 42 million people world­
wide. Coverage was so widespread that Washington 
began to pay attention, and in March, Tomasz was 
contacted by the Office of Technology Assessment to 
help them prepare a report to Congress on the public 
health dimensions of bacterial antibiotic resistance. 
Tomasz has been active internationally as well. 
Together with his friend, the South African scientist 
Keith Klugman, he organized 1n April of last year a 
conference in Prague focusing on the multidrug-resis­
tant pneumococcus in Eastern Europe. Tomasz, who 
had marshaled a network of investigators to collect 
data on resistance in the former Eastern Bloc coun­
tries, found signs of increasing resistance in Hungary, 
Croatia, Bulgaria and Slovakia. 
Above, Dr. Tomasz surrounded by some members of the microbiology 
laboratory who hail from 11 countries. 
-
A few days later in May, while still in Prague, 
Tomasz was a plenary speaker at the International 
Society of Infectious Disease conference addressing 
the global threat posed by bacterial resis­
Instead of 
tance. Both Prague meetings were stand­
ing-room-only events, generating much 
professional interest. indiscriminate killing 
with drugs, which inspires In July, Tomasz, along with Nobel 
laureate, Rockefeller University professor 
and former president Joshua Lederberg, 
was asked to serve on a new task force on 
germs to develop and 
share new resistance 
strategies, more antibiotic resistance organized by the 
selective approaches 
American Society of Microbiology. 
Lederberg was coauthor of the seminal 
1992 National Academy of Sciences are called for. 
report, "Microbial Threats to Health in 
the United States," which first brought 
national and international attention to the larger 
issues of pathogenic microbes. Lederberg's laboratory 
was also one of twelve at Rockefeller that joined with 
Tomasz to start a new campus research initiative on 
microbial antibiotic resistance and disease. 
New Hope: Back to the Future 
The aim of the new Rockefeller research program 
that Tomasz has proposed is to develop knowledge 
and strategies for combating the five types of resistant 
bacteria that pose the greatest threat to public health: 
tuberculosis, Staphylococcus aureus, coagulase-nega-




























tive staphylococci, pneumococci, and enterococci. 
"Such a program should revitalize interactions 
among laboratories with complementary skills," says 
Tomasz. "It will also provide the structure for a mod­
ern and exciting interdisciplinary training program for 
graduate and postgraduate trainees. In addition, clini­
cal research in antibiotic resistance will be expanded 
at The Rockefeller University Hospital." The plan 
also includes studies in the molecular epidemiology of 
resistance to be conducted in collaboration with sever­
al hospitals in the U.S. and abroad. 
It is no coincidence if the mission behind these 
initiatives sounds familiar. As Rockefeller University 
President Torsten Wiesel told participants at the July 
1993 workshop, it was the deadly epidemics of infec­
tious diseases that prompted the foundation of The 
Rockefeller Institute for Medical Research in 1901 as 
the nation's first biomedical research center. "The 
founders of the Institute understood clearly that the 
ultimate control of these devastating microbial dis­
eases required first that scientists turn their attention 
to the understanding of the nature and mechanism of 
infectious disease," said Wiesel. It will be the mission 
of modern microbiologists at Rockefeller and else­
where, he emphasized, to readdress themselves to this 
public health issue now, with emphasis on antibiotic­
resistant microbes that cause invasive diseases. 
Tomasz believes that the best hope lies in rethink­
ing our entire approach to treating infectious diseases. 
-
411 .. 
Above, Worldwide spread of a multiply drug resistant clone (capsule type 
23F) of pneumococcus, probably originating in Spain. Using molecular "fin­
gerprints" to identify the offspring of drug-resistant pneumococcus, the 
Tomasz lab has helped track the disease-causing bacteria all over the globe. 
Instead of indiscriminate killing with drugs, which 
inspires germs to develop and share new resistance 
strategies, more selective approaches are called for. 
"For example, you could aim drugs at the specific dis­
ease-causing components of the bacteria, or at the 
dangerous response they provoke in the host," he sug­
gests. "The result would be more selective, lower pro­
file drugs that would threaten a bug's bad habits 
rather than its survival, making the drugs far less like­
ly to become sitting ducks for resistance." Tomasz is 
convinced that the design of such future drugs will 
require that the pharmaceutical industry develop close 
alliances with microbiology laboratories studying 
mechanisms of bacterial physiology, gene transfer and 
disease. 
In his own efforts to find new molecular strategies 
that can be mobilized against bacteria, Tomasz has 
reinstated studies in his lab on genetic transformation. 
So he,  and other pneumococcal researchers at 
Rockefeller, have truly come full circle. Pneumonia, 
the leading killer at the beginning of the century, led 
to Avery's pioneering work on pneumococcus and the 
discovery that genes are made of DNA. Now DNA 
techniques are helping Tomasz and others study the 
pneumococcus with greater precision in an attempt to 
better understand antibiotic resistance and conquer 
pneumococcal disease. Says Tomasz, "That incredible 
little bug, the pneumococcus, still has many lessons to 
teach us." � 
e 
stigations 
y Avery and 
his school between 1913 and 1940 
have provided the pattern, the master
plan, used by our generation for the
immunochemical study of infectious
processes.' ' 197 6
Rene J. Dubos 
xperiments 
gested that future
experiments would show that all genes 
were composed of DNA. If true, this
meant to Francis [Crick] that proteins 
would not be the Rosetta Stone for
unravelling the true secret of life. 
Instead, DNA would have to provide
the key to enable us to find out how the 
genes determined, among other charac­
teristics, the color of our hair, our eyes, 
most likely our comparative intelli­
gence, and maybe even our potential to
its details, the 
ry contribution 
of Avery, MacLeod and McCarty was
the refocusing on DNA by a generation
of chemical biology. Certainly that was 
its precise impact on the initiation of
my own scientific career.' ' 1979 
Joshua Lederberg 
Nobel laureate,former president of 
The Rockefeller University, on the 35th 
anniversary of the Avery discovery 
microbiologist, 
The Rockefeller University 
amuse others.' ' 1968
James D. Watson 
edis¢overy that 
·/Ir. is �,ditary material [is] per­
haps the most important discovery in 
biology of the 20th century.' ' 1985
Paul A. Marks 
M.D., president, Memorial 
Sloan-Kettering Cancer Center 




� ery, McCarty and 
MacLeod conducted at Rockefeller 
University during World War II changed 
the course of the world, reduced suffer­
ing and contributed immeasurably to the 
quality of life as we know it.' ' 1994
U.S. Senator 
Daniel P. Moynihan 
entered into The Congressional Record, 
February 2, 1994 
t inten��t · ng 
and portentous biological experiment 
of the 20th century .... '' 1985 
at this great university, this extraordi­
nary discovery has, in my judgment, 
more than justified-all by itself-the 
great hope and aspiration of my 
grandfather and father when they 
established this institution in 1901. It 
has given to the world what they 
hoped for: the beginning of the under­
standing of the inner mysteries of life 
and disease.' ' 1994
Sir Peter Medawar 
David Rockefeller 
chairman of the Executive Committee 
of the Board of Trustees, 
The Rockefeller University 
dark con-
grammar of biology .... Avery gave 
us the first text of a new language, 
or rather he showed us where 




Nobel laureate, immunologist 
le discovery 
biological evolution which continues 
to transform our view of nature in 
its most intimate details .... ' ' 
1985 
Lewis Thomas 
physician, scientist and essayist 
November 19, 1993 
James D. Watson, Nobel laureate 
and director of the Cold Spring 
Harbor Laboratory, launches the 
celebration with a public 1ecture 
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ctures 
December 29 & 30, 1993 
Above, as part of a year-long focus 
on DNA research, molecular 
DNA researchers John Kuriyan 
and Stephen K. Burley discuss 
"da Vinci and Darwin and the 
Molecules of Life" at the annual 
Alfred E. Mirsky Christmas Lectures. 
nome 
February 2, 1994 
David Botstein, professor 
and chair of the genetics 
department at Stanford University, 
d�livers a public lecture on the 
Human Genome Project. 
le 
February 3, 1994 
Nobel laureate Alfred Day Hershey, 
left, and Professor Emeritus Rollin 
Hotchkiss were among six pioneers 
active in the field of genetic 
research between the publication 
of the Avery paper and the discov­
ery of the double-helical structure 
of DNA who gathered for a round­
table discussion. The others were 
Visiting Professor Robert Olby, 
chair; Professor Joshua Lederberg; 
Professor Emeritus Maclyn 
McCarty; Erwin Chargaff; and 
Seymour Cohen. 
February 1, 1994 
On the anniversary of the publication 
of the landmark paper, Professor 
Emeritus Maclyn McCarty, center, 
the sole surviving member of the 
Avery team, is honored in the RU 
Hospital by, from left to right, Deputy 
Mayor of New York City John Dyson, 
Chairman of the Board's Executive 
Committee David Rockefeller, 
President Torsten Wiesel, and 
Physician-in-Chief Jules Hirsch. 
ation 
May 6, 1994 
Professor Jan Breslow, above, 
chairs a scientific symposium 
featuring lectures by a new genera­
tion of DNA researchers at the 
university: Professor Stephen K. 
Burley, Associate Professor 
Frederick Cross, and Associate 




Oswald T. Avery, 
Colin MacLeod and 
Maclyn McCarty. 
April 18, 1994 
Nancy Wexler, professor at 
Columbia University and chair of the 
Human Genome Project's Committee 
on Ethical, Legal, and Social Issues, 
speaks on DNA technology and its 
consequences at a public lecture. 
February 4, 1994 
Professor Emil Gotschlich, 
center, chairs a scientific sympo­
sium that features Robert Austrian 
of the University of Pennsylvania 
School of Medicine, left, and John 
Robbins of the National Institutes 
of Health. The symposium reviewed 
Avery's scientific accomplishments 
and subsequent developments in 





Huntington's Disease Gene 
By Mika Ono Benedyk 
The 1944 Avery paper did not just usher in a new era 'of molecular biology and genetics. 
The revolution in lmowledge also created a host of new ethical dilemmas never encountered before. 
As part of its "50 Years of DNA" celebration, The Rockefeller University invited renowned 
Columbia professor and bioethicist Nancy Wexler to discuss some of the personal and ethical rami­
fications of our brave new genetic world. 
Of all possible fates, 
having the genetic disorder that 
causes Huntington's disease is one 
that no person would choose. The 
symptoms, which usually set in at 
mid-life, are subtle at first: lack of 
coordination, small twitches, memory 
loss, depression, irritability. But as 
the disease progresses-over the 
course of 10 to 20 agonizing years­
part of the brain inexorably degener­
ates. Those afflicted lose the ability 
to control their movement and their 
arms and legs flail about wildly. 
Near the end, and the end is inev­
itably death, patients are emaciated, 
incontinent, unable to speak, yet still 
able to grasp the tragedy of 
their demise. 
Nancy Wexler, who spoke 
at The Rockefeller University in 
April as part of its 50th anniversary 
celebration of the discovery there 
that genes are made of DNA, has 
been at the forefront of bringing 
modern genetic technology to 
bear on this disease. Her work 
helped to find a genetic marker for 
the illness, and then to identify 
the genetic defect that causes 
Huntington's disease. While these 
discoveries have brought new 
hope for a cure, they have also 




When Wexler was 2 3, she 
learned that her mother, like three 
of her uncles and her grandfather, 
had Huntington's disease. In itself 
the news was devastating. But it also 
had implications for her sister and 
herself: it meant that they each had 
a 50 percent chance of developing 
the illness themselves later in life. 
The days-and years-after 
Wexler's mother's diagnosis were try­
ing. Wexler and her sister decided 
immediately never to have children. 
When Wexler was 23, 
she learned that her mother, 
like three of her uncles 
and her grandfather, had 
Huntington's disease. 
Wexler battled depression. But 
everyone in the family also became 
passionately committed to the strug­
gle against the disease. 
Wexler, who had just graduated 
from Radcliffe, continued with her 
plans to pursue a Ph.D. in psycholo­
gy, focusing on families with 
Huntington's. After graduating from 
the University of Michigan in 1974, 
she moved to New York to teach and 
open a private practice. It wasn't long 
before she was appointed executive 
director of Congress's Commission 
for the Control of Huntington's 
Disease and Its Consequences. After 
the commission's work was over, she 
became a health science administra­
tor heavily involved in Huntington's 
issues at the National Institute o{ 
Neurological, Communicative 
Disorders and Stroke. 
T
he Search 
for the Gene 
Wexler had great faith that DNA 
could provide the clue to curing 
Huntington's disease. She felt that 
finding the gene would lead directly 
to a treatment. But for many years, 
the task seemed Herculean: Hunting­
ton's disease could be caused by a flaw 
in any one or several of the 3 billion 
base pairs in the human genome. 
Then, in the early 1980s, fresh 
hope appeared. David Botstein (who 
also spoke at Rockefeller as part of 
the "50 Years of DNA" celebration) 
and his colleagues had developed a 
hypothesis that variability in the 
DNA close to a disease-causing gene 
could be used to demarcate the gene's 
approximate location. Disregarding 
the warnings of many reputable sci­
entists that finding a marker could 
take over half a century, Wexler 
pushed ahead. 
Mika Ono Benedyk, a writer, works 
at the Rockefeller Group. 
The search took her to the shores of 
Lake Maracaibo, in Venezuela. 
There, in several small, poor fishing 
villages, lay one of the largest com­
munities in the world afflicted with 
Huntington's disease. Throwing 
themselves into the quest, Wexler and 
her colleagues built a pedigree of 
almost 13,000 people and collected 
blood samples which would come to 
number over 3,000. Jim Gusella at 
Massachusetts General Hospital, who 
was also studying a family with 
Huntington's from Iowa, extracted 
the DNA from the Venezuela samples 
and looked for a genetic marker that 
"traveled" with Huntington's disease 
in a family. 
In an incredible stroke of 
luck, the Gusella lab together with 
P. Michael Conneally of Indiana
University stumbled upon a mark
er on the 12th try. Almost all those
with Huntington's disease had one
form of the marker while their
healthy relatives had another. Wexler
was jubilant. The location of the
probe was quickly mapped to the top
of the short arm of chromosome 4,
and the results were published in
Nature in November 1983, just three
years after the effort began.
E
ureka! 
The next goal was to find 
the exact location of the gene, 
isolate it and learn its secret-what 
Wexler at first assumed would be 
a quick and easy task. 
Wexler helped marshal the 
forces of six scientific groups around 
the world to collaborate instead of 
Above. Nancy Wexler sits behind a sculpture of the 
DNA double helix. Right. Wexler's quest for the 
gene that causes Huntington's disease took her to 
Lake Maracaibo in Venezuel,p, one of the largest 
communities in the world afflicted with the disease. 
compete in their search for the gene, 
a highly unusual effort in the often 
cutthroat arena of science. The 
groups were led by: Francis Collins 
of the University of Michigan; 
Hans Lehrach of the Imperial 
Cancer Research Fund, London; 
Peter S. Harper of the University 
of Wales College of Medicine; 
David Housman of the Massachusetts 
Institute of Technology; Gusella; and 
John Wasmuth of the University of 
California, Irvine. One year stretched 
into two, then three ... Almost 10 
years passed without isolating the 
gene. Some scientists speculated that 
there was no Huntington's disease 
gene. Wexler likened the effort to 
"crawling up Mount Everest." 
The Gusella group was focus­
ing on one region of the chroma-
some as part of the collaborative 
effort. One night, Marcy Mac­
Donald and Christine Ambrose of 
Gusella's lab discovered the end of 
a gene where there were 48 repeats 
of one sequence of nucleotide bases 
in a DNA sample from a Hunting­
ton's disease sufferer: cytosine, 
adenine, guanine (CAG). They 
checked against a sample from 
someone without Huntington's: 
There were only 18 repeats of this 
sequence. Could it be so simple? 
Soon, the researchers were calling 
Wexler with the good news: They 
had found the long-sought gene. 
Wexler is still filled with wonder 
at the finding. "It strikes me as stag­
gering the enormously subtle differ­
ence between life and death," she 
said. "If you have 11 to 34 repeats 
of this CAG, you are going to live. 
If you have 3 more, from 3 7 to 100, 
you are dead." 
The researchers also found that 
the youngest victims had the most 
repeats (although the oldest did not 
have the fewest), and that the number 
of repeats tended to expand slightly as 
the gene was passed from generation 
to generation. The Huntington's 
Collaborative Research Group 
published their conclusions last 




Although from a scientific 
perspective the advances in 
Huntington's disease have been 
astounding, from a medical point 
of view little has changed. There 
is no cure. There is no treatment. 
There is now only a genetic test 
that can tell individuals, before they 
develop symptoms, whether they 
will come down with the disease at 
some undetermined time later in life. 
The test itself poses new dilemmas 
for those at risk for the disease. 
"When [the test] first became 
available, my sister, father and I had 
no question about taking it," said 
Wexler in an interview with Columbia, 
the magazine of Columbia University 
where Wexler is now a professor. "My 
sister and I thought, 'Isn't this fantas­
tic!' We could have children! My 
father could stop saving money for 
Soon we will all be facing the 
question of whether we want 
to know what is ahead in our 
own and our children's future. 
nursing homes and retire. When we 
thought more about it, however, my 
father was the first to say, 'Wait a 
minute! I don't want to know if either 
of you has a bad outcome. One bad 
outcome and we're all three dead."' 
As Wexler acknowledges, there 
are many compelling reasons for 
those at risk to take the test. The 
absence of the Huntington's gene 
Above, Wexler hugs a Venezuelan child who 
carries the Huntington's gene. 
would be a tremendous relief. Even 
if the results show the presence of 
the genetic defect, one's family, 
career and finances could more 
easily be planned. 
On the other hand, the reasons 
for not taking the test can be just as 
compelling. To learn that you have 
the Huntington's gene and will die 
an early and prolonged death can be 
devastating for you and your family: 
Some who have tested positive have 
attempted suicide. And even a posi­
tive result leaves uncertainty: You do 
not know when the disease will begin 
its insidious advance. In fact, some 
individuals who know they have the 
genetic mutation begin to think of 
themselves as sick before they come 
down with symptoms, adopting a 
"sick identity" in the face of the 
agonizing ambiguity about when 
the disease will strike. 
Even individuals who test nega­
tive are not always as euphoric as 
they had thought they would be. 
They may feel guilty that siblings and 
parents have the Huntington's gene 
when they don't. Or they may have 
built their identities around being at 
risk-abandoning commitments, for­
going children, living life in the fast 
lane-and be unprepared to learn that 
they are ordinary, vulnerable to other 
diseases, and responsible for their lives 
and futures. 
The prenatal test for Hunting­
ton's poses a similar dilemma. On 
the one hand, you can have a fetus 
tested for the Huntington's gene so 
that you won't bring children into 
the world who will later develop 
the disease. On the other, there is 
no medical justification to take the 
test unless you are willing to abort 
a fetus with the genetic flaw. 
Underlining how personal and 
difficult these dilemmas are, Wexler 
will not say whether she has taken the 
test for the Huntington's gene, only 
that these decisions are complex and 
can change given different circum­
stances and period in the life cycle. 
The genetic underpinnings of 
more and more diseases, such as heart 
disease, diabetes, colon cancer and 
breast cancer, are being revealed. For 
some of these diseases, early diagnosis 
can prove lifesaving. Soon we will all 
be facing the question of whether we 
want to know what is ahead in our own 
and our children's future, and whether 




A cure for Huntington's, and other 
genetic diseases, would eliminate 
the dilemmas of testing in a single 
stroke. But such developments are 
a long way off. Researchers at The 
Rockefeller University and other insti­
tutions are exploring the possibility 
of using gene therapy-where healthy 
genes are inserted into a sick person's 
body-to treat certain genetic diseases 
such as cystic fibrosis. But such experi­
ments are still in very preliminary 
stages, and treating a neurological 
disease such as Huntington's would 
pose many additional challenges as the 
brain is a very delicate and complicat­
ed target. 
In the meantime, Wexler believes 
that we need to face the widening 
gap between our biological under­
standing and society's ability to 
encompass these new developments. 
As chair of the joint National Insti­
tutes of Health/Department of Energy 
Ethical, Legal and Social Issues 
Working Group, Wexler has struggled 
with responding to some of the new 
issues posed by genetic technology. 
These challenges include ensur� 
ing that those being tested understand 
the risks of learning their genetic 
status and providing enough counsel­
ing to help them deal with the results. 
Other challenges are protecting the 
privacy of genetic information and 
restricting its use so that it cannot be 
used to deny employment, stigmatize 
individuals for having "undesirable" 
genes or prevent access to health care. 
Wexler is especially worried about 
the potential for abuse by insurance 
companies. As it is, she points out, 
she herself would normally be totally 
uninsurable-not because she is sick, 
but because of her genetic risk. As 
genetic technology advances, insur­
ance companies will have more and 
more opportunities to deny or limit 
coverage. "We have to be very explicit 
and very unified in fighting this kind 
of pernicious activity that distorts the 
way health care is delivered in this 
nation," she said. 
Is Wexler sorry that she helped 
open Pandora's box, playing a part in 
ushering in this uncharted new age of 
genetic information? While she admits 
that for a time we may have the worst 
of all possible worlds-limited or no 
treatments, unrealistic expectations, 
insurance repercussions-she is still 
optimistic about the future. One day, 
she hopes, genetic technology will lead 
to a better world, one in which people 
will no longer have to suffer the worst 







Above. DNA sequence 
analysis of the (CAG)n
repeat. In a person 
without Huntington's 
disease, there are only 
18 repeats ( left); the 
DNA sequence of a per­
son with the disease 









· here fa _ othing 1· n the known universe to com.­
pare with t e human brain." So reads the 
opening of the new book, The Hostage Brain, 
written by Roe efeller Professor Bruce McEwen
and veteran jeienc rnalist Harold M. ScB.mecJ
k, Jr. 
In the 30_0 Jr so pages that follow, the authors proceeito:.Show Just how wondrous the human brain really is!
The new b00k,. ·published by The Rockefeller 
University Pr. s, describes multiple influences on the
b&in such ,.as the surprising interactions that occur 
between the brain and the immune system, with hor­
mones 'from the immune system affecting the brain, 
and the brain innervating cells of the immune system
and bombarding them with neurotransmitters and 
ormones. The book also describes the devastating
impact of neurological diseases such as Alzheimer's
and schizophrenia. It chronicles the impact of our
inner biological clocks on memory, alertness and
mood. It tracks the effect of aging on the brain. 
And it explores the impact of a wide range of experi­
ences such as learning, stress and interpersonal rela­
ti<_;nships on the body's most complicated organ. Many of McEwen's insights into the hostage brain
come from work in his own laboratory, which focuses
e effect of sex and stress hormones on the brain.
He first caught the bug for communicating these 
insiglits when he gave the Alfred E. Mirsky Christmas
Lectures for High School Students in 1973. Three 
years ago, McEwen teamed up with Schmeck, a veter­
an science reporter who had recently retired from The 
New York Times. Schmeck's distinguished career cov­
ering scientific research provided him with a t{easure 
trove of experience and anecdotes to make the science
come alive.:, ::fogetper, the two authors worked with 
scientific "'tll�strator, Lyclia Kibiuk to produce a book
that aims to "reach out to every level of scientific 
understan}ling, and to allow people who are not scien­
tists to lear0. about the brain." McEwen hopes that
Above, Dr. Bruce McEwen, (right), and Harold M. 
Schmeck, Jr., at the book launching party. 
the book will be read by interested lay people, and 
also used in high schools, adult evening schools and
certain medical school settings. 
Each audience may take from the book different 
levels of understanding, but McEwen hopes that every
reader will hear the book's fundamental message. 
He says, "If you're a hostage, then there has to be a
ransom, or a way of breaking the bonds. And that 
really has to do with using our intelligence to under­
stand how the brain works. Many of our most vexing
problems-violence on our streets, stress in our lives, 
anxiety, mental illness-are problems of behavior and
brain function that can be addressed more effectively
by understanding how the brain operates and how
it is capable of changing. 
"The challenge to all of us is to use our brains\ 
to understand our brains and our behavior because 
in the end, our !?rains are mainly hostage t� one '
thing: ignorance?""'-
Hardcover ($39,,JS,) and softcover ( :Z .95) copies 
o(The Hosfage Brain are available fwm 'Ehe Rockef,eller
University Press Order Service, 212.327.8'51<2 or 
fax 212.327.7944. 
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Blue colonies of a pneumococcal strain with a genetic defect in an exported 
protein, left, compared to the white parental strain (magnification: 20). 
Capitalizing on the 1944 discovery of Avery, Macleod and McCarty, 
Rockefeller University investigator Robert Masure designed a genetic 
strategy in 1994 to systematically map the surface of pneumococcus. 
